Navigation Links
Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
Date:2/13/2013

ST. LOUIS, Feb. 13, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ:  SIAL), a leading Life Science and High Technology company (the "Company"), announced an increase of 7.5% in its quarterly cash dividend to $0.215 per share.  The increased dividend was approved by the Company's Board of Directors on February 12, 2013 and is payable on March 15, 2013 to shareholders of record at the close of business on March 1, 2013.

The Company also announced it will be presenting at the following investor conferences in February:

  • Leerink Swann Global Healthcare Conference 2013 on Thursday, February 14, 2013 in New York City, presenting at 12:00 P.M. (Eastern).
  • 2013 Citi Global Healthcare Conference on Monday, February 25, 2013 in New York City, presenting at 9:35 A.M. (Eastern).

Interested parties may listen via live audio broadcast and view the presentation slides over the internet available at http://investor.sigmaaldrich.com/.  Users can click the "Webcast" icon to access the files.

About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company.  Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing.  The Company has customers in life science companies, university and government institutions, hospitals and in industry.  Over one million scientists and technologists use its products.  Sigma-Aldrich operates in 38 countries and has nearly 9,000 employees providing excellent service worldwide.  The Company is committed to accelerating customer success through innovation and leadership in Life Science, High Technology and Service.  For more information about Sigma-Aldrich, please visit its award winning web site at www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
2. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
3. Sigma-Aldrich Corporation Announces New Credit Facility
4. Sigma-Aldrich Elects Michael Marberry As Director
5. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
6. Sigma-Aldrich Corporation Will Hold Its Annual Business Review March 21, 2013
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Luminex Corporation to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):